Orexo and SVF Vaccines Evaluate Powder-Based Formulation Technology for mRNA Vaccines
Key Points
- Orexo and SVF Vaccines launched a research collaboration to test AmorphOX powder technology for stabilizing LNP-encapsulated mRNA vaccines.
- The work will check whether spray drying preserves LNP structure and mRNA biological activity.
- Positive feasibility results could lead to intranasal vaccine exploration and broader biologics applications.
Orexo AB and SVF Vaccines AB have launched a research collaboration to investigate the use of Orexo’s proprietary AmorphOX powder-based drug delivery technology for stabilizing lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines. The research will focus on whether LNP-mRNA formulations can undergo spray drying using AmorphOX while retaining the structural characteristics of the lipid nanoparticles and the biological activity of the encapsulated mRNA.
LNPs are widely used in nucleic acid-based therapeutics because they protect fragile mRNA molecules and facilitate their delivery into cells. However, maintaining the stability of both the genetic material and its lipid carrier can present formulation challenges, particularly during storage, handling and distribution. Converting these formulations into stable powders could offer an alternative to conventional liquid-based products, potentially simplifying transportation and storage while providing greater flexibility in vaccine development and administration.
The partnership combines Orexo’s experience in powder formulation and intranasal drug delivery with SVF Vaccines’ capabilities in vaccine development. The initial research will establish whether the AmorphOX platform can accommodate LNP-mRNA formulations without compromising critical product characteristics.
If the feasibility work produces positive results, the companies may explore additional development opportunities, including potential intranasal vaccine administration. Such an approach would require further investigation of delivery efficiency, tolerability and the ability to generate appropriate immune responses at mucosal surfaces. The collaboration also provides an opportunity to assess whether Orexo’s powder formulation technology could have applications beyond vaccines, including other biologic drug products. The initial studies are exploratory, with successful preservation of nanoparticle integrity and mRNA functionality serving as key considerations in determining the direction of subsequent development.
Visit www.orexo.com to learn more.
Total Page Views: 12
